The "Ultimate Triple PET": 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer. (13th August 2021)

• Record Type: Journal Article
• Authors: McClenathan, Matthew; Peacock, Justin G.
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 2(2022)
• Page Start: e161
• Page End: e164
• Publication Date: 2021-08-13
• Subjects: FDG -- PET -- fluciclovine -- DOTATATE; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003853
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent 68 Ga-DOTATATE PET/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. 18 F-FDG PET/CT was performed to evaluate for cardiac and mediastinal sarcoidosis, revealing a lack of cardiac sarcoidosis, but probable mediastinal sarcoidosis. 18 F-Fluciclovine PET/CT was then performed for possible prostate metastases, revealing the patient's known prostate cancer. Three different PET radiopharmaceuticals revealed 3 different processes in a single patient within a 195-day period, demonstrating the power of nuclear medicine diagnostics.